Dr. John A. Chabot

Dr. John A. Chabot, MD, is a globally esteemed surgical oncologist and a leading authority in pancreatic and hepatobiliary surgery. He serves as the David V. Habif Professor of Surgery and Chief of the Division of GI/Endocrine Surgery at Columbia University Irving Medical Center, where he is also Executive Director of the Pancreas Center. Dr. Chabot received his medical degree from Dartmouth Medical School and completed his surgical residency and fellowship at Columbia-Presbyterian Medical Center. Board-certified in general surgery, he has dedicated his career to improving surgical care for complex pancreatic diseases and has performed thousands of advanced procedures, including Whipple resections and minimally invasive pancreatic surgeries.

Dr. Chabot is widely recognized for his innovative contributions to the surgical treatment of pancreatic cancer, including the development and refinement of robotic and laparoscopic techniques that improve outcomes and reduce recovery times. As a pioneer in multidisciplinary pancreatic care, he has helped shape national protocols for managing borderline-resectable and locally advanced pancreatic tumors. He has led numerous clinical trials and research initiatives aimed at improving early detection, surgical outcomes, and survival in pancreatic cancer. His work has been published extensively in peer-reviewed journals and has influenced clinical standards for hepatopancreatobiliary surgery nationwide.

Beyond his clinical and research accomplishments, Dr. Chabot is a dedicated mentor and educator, committed to training the next generation of surgical oncologists. He is a frequent lecturer at national conferences and has served in leadership roles in major surgical societies. Known for his compassionate, patient-centered approach, Dr. Chabot emphasizes personalized care and collaborative treatment planning. Through his leadership in surgery, research, and education, Dr. Chabot continues to advance the field of pancreatic and hepatobiliary oncology, offering hope to patients facing some of the most challenging gastrointestinal cancers.